We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Microsoft, CVS Health, Lockheed Martin, Berkshire Hathaway and Mitsubishi UFJ Financial Group
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 8, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , CVS Health Corp. (CVS - Free Report) , Lockheed Martin Corp. (LMT - Free Report) , Berkshire Hathaway Inc. (BRK.B - Free Report) and Mitsubishi UFJ Financial Group, Inc. (MUFG - Free Report)
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Microsoft, CVS Health and Lockheed Martin
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., CVS Health Corp. and Lockheed Martin Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Microsoft shares have declined -14.9% over the past year against the Zacks Computer - Software industry's decline of -22.0%. The company's increased spending on Azure enhancements amid stiff competition in the cloud space from Amazon is likely to dent margins. Nevertheless, the company's performance is benefiting from strength in its Azure cloud platform amid accelerated global digital transformation.
Teams' user growth is gaining from continuation of remote work and mainstream adoption of hybrid/flexible work model. Recovery in advertising and the job market boosted LinkedIn and Search revenues. Solid uptake of new Xbox consoles is aiding the gaming segment performance.
The company is witnessing growth in user base of its different applications including Microsoft 365 suite, Dynamics and Power Platform. Microsoft expects Surface revenues to grow in the mid-teens range, driven by strong demand for premium devices.
CVS Health's shares have outperformed the Zacks Retail - Pharmacies and Drug Stores industry over the past year (+16.6% vs. +1.7%). The company's robust sales growth across all three operating segments drove the top-line results. The extended cough, cold and flu season boosted sales in the Retail and Pharmacy businesses.
Within the Health Care Benefits arm, the continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services instills optimism. Its raised EPS guidance for 2022 is indicative of this growth momentum continuing.
However, the contraction of margins does not bode well. The decline in COVID-19 vaccinations and testing sales is a downside. Persistent pharmacy reimbursement headwinds also continued to impact business results.
Lockheed Martin's shares have outperformed the Zacks Aerospace - Defense industry over the past year (+23.0% vs. -32.9%). The company remains the largest U.S. defense contractor, with a steady inflow of orders from its leveraged presence in the Army, Air Force, Navy and IT programs. Steady contract flows and subsequent backlog growth bolster its long-term revenue prospects.
The F-35 program continues to be a key growth program for the company's Aeronautics business segment and boosts its sales prospects. Budgetary provisions tend to boost its business.
Yet, the tiff between the U.S. and Turkey on the latter's accepting of Russian products might hurt Lockheed's component supply from Turkey. The company is facing performance issues concerning some of its products, which, in turn, may hamper results. Also, uncertainties revolving around possible sanctions from China on Lockheed might impact the company.
Other noteworthy reports we are featuring today include Berkshire Hathaway Inc. and Mitsubishi UFJ Financial Group, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Microsoft, CVS Health, Lockheed Martin, Berkshire Hathaway and Mitsubishi UFJ Financial Group
For Immediate Release
Chicago, IL – September 8, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , CVS Health Corp. (CVS - Free Report) , Lockheed Martin Corp. (LMT - Free Report) , Berkshire Hathaway Inc. (BRK.B - Free Report) and Mitsubishi UFJ Financial Group, Inc. (MUFG - Free Report)
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Microsoft, CVS Health and Lockheed Martin
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., CVS Health Corp. and Lockheed Martin Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Microsoft shares have declined -14.9% over the past year against the Zacks Computer - Software industry's decline of -22.0%. The company's increased spending on Azure enhancements amid stiff competition in the cloud space from Amazon is likely to dent margins. Nevertheless, the company's performance is benefiting from strength in its Azure cloud platform amid accelerated global digital transformation.
Teams' user growth is gaining from continuation of remote work and mainstream adoption of hybrid/flexible work model. Recovery in advertising and the job market boosted LinkedIn and Search revenues. Solid uptake of new Xbox consoles is aiding the gaming segment performance.
The company is witnessing growth in user base of its different applications including Microsoft 365 suite, Dynamics and Power Platform. Microsoft expects Surface revenues to grow in the mid-teens range, driven by strong demand for premium devices.
(You can read the full research report on Microsoft here >>>)
CVS Health's shares have outperformed the Zacks Retail - Pharmacies and Drug Stores industry over the past year (+16.6% vs. +1.7%). The company's robust sales growth across all three operating segments drove the top-line results. The extended cough, cold and flu season boosted sales in the Retail and Pharmacy businesses.
Within the Health Care Benefits arm, the continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services instills optimism. Its raised EPS guidance for 2022 is indicative of this growth momentum continuing.
However, the contraction of margins does not bode well. The decline in COVID-19 vaccinations and testing sales is a downside. Persistent pharmacy reimbursement headwinds also continued to impact business results.
(You can read the full research report on CVS Health here >>>)
Lockheed Martin's shares have outperformed the Zacks Aerospace - Defense industry over the past year (+23.0% vs. -32.9%). The company remains the largest U.S. defense contractor, with a steady inflow of orders from its leveraged presence in the Army, Air Force, Navy and IT programs. Steady contract flows and subsequent backlog growth bolster its long-term revenue prospects.
The F-35 program continues to be a key growth program for the company's Aeronautics business segment and boosts its sales prospects. Budgetary provisions tend to boost its business.
Yet, the tiff between the U.S. and Turkey on the latter's accepting of Russian products might hurt Lockheed's component supply from Turkey. The company is facing performance issues concerning some of its products, which, in turn, may hamper results. Also, uncertainties revolving around possible sanctions from China on Lockheed might impact the company.
(You can read the full research report on Lockheed Martin here >>>)
Other noteworthy reports we are featuring today include Berkshire Hathaway Inc. and Mitsubishi UFJ Financial Group, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.